LOBE — Lobe Sciences Share Price
0.000.00%
Last trade - 00:00- CA$3.43m
- CA$3.79m
- CA$0.84m
- 28
- 12
- 28
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -263.42% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.77 | 0.88 | n/a | n/a | 0.84 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.
Directors
- Jonathan Gilbert CHM (48)
- Philip Young CEO
- Brian Zasitko CFO
- Leighton Bocking IND
- Faizaan Lalani IND
- Michael Petter IND
- Last Annual
- August 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- May 13th, 2010
- Public Since
- June 19th, 2012
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 171,560,392
- Address
- 1400-1199 West Hastings Street, VANCOUVER, V6E 3T2
- Web
- https://www.lobesciences.com/
- Phone
- +1 6048349499
- Auditors
- Davidson & Company LLP
Upcoming Events for LOBE
Q3 2024 Lobe Sciences Ltd Earnings Release
Similar to LOBE
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Acreage Holdings
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
FAQ
What is the Lobe Sciences share price?
As of Today at 21:50 UTC, shares in Lobe Sciences are trading at CA$0.02. This share price information is delayed by 15 minutes.
How has the Lobe Sciences share price performed this year?
Shares in Lobe Sciences last closed at CA$0.02 and the price had moved by -50% over the past 365 days. In terms of relative price strength the Lobe Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -54.96% over the past year.
What are the analyst and broker recommendations for Lobe Sciences?
There is no consensus recommendation for this security.
What is the Lobe Sciences dividend yield?
Lobe Sciences does not currently pay a dividend.
Does Lobe Sciences pay a dividend?
Lobe Sciences does not currently pay a dividend.
When does Lobe Sciences next pay dividends?
Lobe Sciences does not currently pay a dividend.
How do I buy Lobe Sciences shares?
To buy shares in Lobe Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lobe Sciences?
As of the previous close price of CA$0.02, shares in Lobe Sciences had a market capitalisation of CA$2.57m.
Where are Lobe Sciences shares listed?
Here are the trading details for Lobe Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: LOBE
What kind of share is Lobe Sciences?
Based on an overall assessment of its quality, value and momentum Lobe Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lobe Sciences share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Lobe Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lobe Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -26.88%.
As of the last closing price of CA$0.02, shares in Lobe Sciences were trading -34.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lobe Sciences PE Ratio?
The Lobe Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lobe Sciences?
Lobe Sciences' management team is headed by:
- Jonathan Gilbert - CHM
- Philip Young - CEO
- Brian Zasitko - CFO
- Leighton Bocking - IND
- Faizaan Lalani - IND
- Michael Petter - IND